A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, ...

Researchers have identified key factors that determine the success of leukemia cell therapies, including DLI, in achieving ...

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...

Columbia Engineering and Irving Institute researchers unveil a significant finding in cancer immunotherapy, uncovering unique ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in cancer immunotherapy ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...

The analysis found that less than fifty percent of enrolled patients deceased after the median follow-up period of 13.5 months, indicating a median survival of over 13.5 Months in the trial vs.

Dana-Farber researchers identified factors predicting the success of donor lymphocyte infusion (DLI) in treating relapsed AML ...

The hospital threatened "to get the law involved," his friend said. "You tell me how that’s right for a man that’s fighting ...